Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

This study is testing a new three-drug combination — BP1001 (an experimental drug), venetoclax (a targeted drug that causes cancer cells to self-destruct), and decitabine (a chemotherapy that reprograms cancer cells) — for people with acute myeloid leukemia (AML), a fast-growing blood cancer. **You may be eligible if...** - You are 18 years or older - You have newly diagnosed AML, secondary AML (arising from a prior blood disorder), or AML that has returned or is not responding to treatment - Your heart, liver, kidneys, and blood counts meet minimum function requirements - Women must be post-menopausal, surgically sterile, or use reliable contraception during and for 30 days after treatment - Men must use contraception during and for at least 30 days after treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have significant heart, liver, or kidney problems - You have an active infection - You have recently been treated with venetoclax or decitabine without response - You have other serious medical conditions making participation unsafe Talk to your doctor to see if this trial is right for you.